NIFTY 500 › Fast Moving Consumer Goods
Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Filings
66 filings of MARICO since January 2025; the newest 40 below.
transcript 20, presentation 18, acquisition 13, board outcome 7, dividend 3, results 2
| Filed | Type | Subject | |
|---|---|---|---|
| 06 Nov 2026 | acquisition Acquisition | Please find attached an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015AI summaryMarico Limited has entered into definitive agreements with the founders of Bonorizon Consumer Ventures Private Limited for a strategic venture to support its international growth strategy. Marico will acquire 51% of Bonorizon's equity share capital and voting rights through primary subscription, in cash, for aggregate consideration of up to Rs. 35 Crores. Bonorizon was incorporated on October 22, 2026 and operates in FMCG and consumer products; its turnover is stated as not applicable. The transaction is expected to complete within 90 days of signing, subject to customary closing conditions; no governmental or regulatory approvals are stated as required. Marico has the right to acquire the remaining equity after 3 years, at a consideration to be determined then, subject to milestones and approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2026 | acquisition Acquisition | Please find attached an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015AI summaryMarico Limited intimated under Regulation 30 that it acquired a further 20% of paid-up share capital of Cosmix Wellness Private Limited for an aggregate cash consideration of Rs. 113.65 Crores, completed on November 6, 2026. Marico's aggregate stake in Cosmix Wellness increases from 60% to 80% of its paid-up share capital. The transaction is a related party transaction on an arm's length basis; promoter/promoter group have no interest in it, and no governmental or regulatory approvals are required. Cosmix Wellness, incorporated January 31, 2022 and based in Bengaluru, owns a digital-first functional wellness brand; its turnover was Rs. 24.32 Crores (FY 2023-24), Rs. 47.25 Crores (FY 2024-25) and Rs. 91.53 Crores (FY 2025-26). The company has the right to acquire the remaining stake after completion of FY29, subject to milestones, approvals and agreed terms. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2026 | transcript Guidance, Results | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, copy of transcript of the earnings conference call held on Monday, November 2, 2026 on the un-audited financial results and operationAI summaryMarico filed the transcript of its Q2 FY27 earnings conference call held on November 2, 2026, on unaudited results for the quarter and half year ended September 30, 2026. Management (Saugata Gupta, MD & CEO) said consolidated revenue grew 13%, EBITDA grew 27% and PAT grew 31% in the quarter, with EBITDA margin at 18.2%, up 200 basis points despite A&P spend rising 44%. For the half year, management said revenue, EBITDA and PAT grew 18%, 26% and 28% respectively. Management raised its annual outlook: teens revenue growth, revenue comfortably above INR15,000 crores, mid-twenties EBITDA growth (up from around 20%), and India volume growth expected in double digits for the full year. Management reiterated a vision of INR20,000 crores revenue by FY30 with mid-teens EBITDA CAGR, aspiring to reach it by 2029. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2026 | presentation | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Management of the Company will be attending investor conferences as per the details AI summaryMarico Limited filed a schedule of its management's attendance at investor conferences under Regulation 30 of the SEBI Listing Regulations, dated November 5, 2026. Event 1: Avendus Spark INDX, one-on-one/group meeting, Monday, November 16, 2026, Mumbai. Event 2: JM Financial Annual India Conference - India Xchange 2026, Tuesday, November 17, 2026 (meeting type and location not stated in the text). The company says the schedule is subject to change and that no unpublished price sensitive information will be shared at the meetings. The presentation used at these meets is available on the company's website. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Nov 2026 | presentation Results | Please find enclosed the Information Update along with an earnings presentation on the un-audited consolidated and standalone financial results of the Company for the quarter and half year ended September 30, 2026.AI summaryMarico filed an Information Update with an earnings presentation on its unaudited consolidated results (Marico Limited and subsidiaries) for the quarter and half year ended September 30, 2026. Consolidated revenue grew 13% YoY, consolidated EBITDA grew 27% with a 200bps margin expansion, and consolidated PAT grew 31%, per the presentation. India business revenue rose 10% YoY and International business revenue rose 23% YoY (in INR terms); domestic volume growth was 10% and International CCG 13%. Consolidated gross margin expanded 600bps, the highest in 50 quarters, and consolidated A&P spends grew 44%, the highest in 51 quarters. Management states the company has delivered high-single-digit volume growth in 7 out of 10 quarters and teens or higher CCG or revenue growth in 9 out of 10 quarters. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Nov 2026 | board outcome Management change, Results | Please find enclosed outcome of the Board Meeting held on November 2, 2026.AI summaryMarico Limited's board, at its meeting held on November 2, 2026, approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with statutory auditors' limited review reports enclosed. The board appointed Mr. Rajan Bharti Mittal (DIN: 00028016), an Independent Director, as Lead Independent Director with effect from November 2, 2026. The statutory auditor's limited review of the consolidated results (B S R & Co. LLP) states nothing has come to its attention that the statement contains any material misstatement; the auditor did not review 5 subsidiaries and relied on other auditors' reports for them. The filing does not state revenue, profit or dividend figures in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 Oct 2026 | transcript | This is to inform you that the Company will hold an investor/analyst conference call on Monday, November 2, 2026 at 6:00 p.m. (IST). During the call, the Management will comment on the financial results and operations for the quarter and haAI summaryMarico Limited has announced an investor/analyst conference call on Monday, November 2, 2026 at 6:00 p.m. IST. The call will cover the financial results and operations for the quarter and half year ended September 30, 2026. Management participants named are Mr. Saugata Gupta (Managing Director & CEO) and Mr. Pawan Agrawal (Group CFO & CEO - International Business). An audio recording and transcript of the call will be published on the company's website after the call. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Oct 2026 | acquisition Acquisition | Please find attached an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015AI summaryMarico Limited has acquired a further 24.09% stake (fully diluted) in Satiya Nutraceuticals Private Limited, raising its aggregate holding from 60% to 84.09%; the current tranche was completed on October 5, 2026 for cash consideration of ₹1,012.03 Crores. The aggregate consideration for the 84.09% stake stands at ₹1,392.07 Crores. The remaining 14.09% stake is to be acquired in July 2027 for a base consideration of up to ₹592 Crores plus milestone-linked additional consideration, subject to definitive agreement terms. The transaction is a related party transaction on an arm's length basis, as the stake is held by the Founders and their relatives/related entities; no governmental or regulatory approvals are required. Satiya Nutraceuticals, which owns the PLIX brand, reported consolidated turnover of ₹864.31 Crores in FY 2025-26, ₹432.84 Crores in FY 2024-25 and ₹155.32 Crores in FY 2023-24. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Sep 2026 | presentation | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Management of the Company will be attending investor conferences as per the details AI summaryMarico Limited filed a schedule of analyst/investor meetings under Regulation 30 of the SEBI Listing Regulations, dated September 10, 2026. Management will attend the 2026 Jefferies India Forum (one-on-one / group meeting) on Thursday, September 17, 2026, in Gurgaon. Management will attend the J.P. Morgan India Conference on Tuesday, September 22, 2026, in Mumbai. The presentation used for such meetings is available on the company website; the schedule is subject to change, and no unpublished price sensitive information will be shared. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Sep 2026 | credit rating Rating | Marico Limited has informed the Exchange about Credit RatingAI summaryMarico Limited intimated that CRISIL Ratings Limited has reaffirmed the credit ratings on the limits of various bank facilities, including its ESG profile. Long-term bank loan facilities: CRISIL AAA/Stable (reaffirmed). Short-term bank loan facilities: CRISIL A1+ (reaffirmed). The rating rationale is available via a link provided in the filing, and the intimation is on the company website. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Sep 2026 | presentation | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Management of the Company will be holding one-on-one/group meetings with investors in AI summaryMarico Limited filed a schedule of analyst/investor meetings under Regulation 30 of the SEBI LODR Regulations. Management will hold one-on-one and group meetings with investors in London as part of a Non-Deal Roadshow organised by Goldman Sachs (India) Securities Private Limited. The roadshow runs from September 7, 2026 to September 8, 2026, and the schedule is subject to change. The company states that no unpublished price sensitive information will be shared at the meetings. The presentation used for these meetings is available on the company website. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 Aug 2026 | transcript Dividend / buy-back, Guidance, Results | We enclose herewith copy of transcript of the 38th Annual General Meeting of the Company held on Thursday, August 6, 2026 at 9.00 A.M. IST through Video Conferencing/Other Audio-Visual Means.AI summaryMarico Limited filed the transcript of its 38th Annual General Meeting, held on August 6, 2026 via video conferencing. Chairman Harsh Mariwala said FY26 consolidated revenue was ₹13,611 Crore, up 26% year-on-year; MD & CEO Saugata Gupta said recurring consolidated profit after tax was ₹1,762 Crore, up 11%, and operating margin was 17.1%, down 265 bps. Management said India business turnover was ₹10,348 Crore, up 28%, with underlying volume growth of 8%, and that the company is aiming for ₹15,000 Crore revenue in FY27 and ₹20,000 Crore by 2030. FY26 dividend was ₹4 per share (400% of face value); average five-year payout was 66% of recurring consolidated net profit. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Aug 2026 | transcript Guidance, Results | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, copy of transcript of the earnings conference call held on Tuesday, August 4, 2026 on the un-audited financial results and operationsAI summaryMarico Limited filed the transcript of its Q1 FY27 earnings conference call held on August 4, 2026, covering the quarter ended June 30, 2026. Management (Saugata Gupta, MD & CEO) said consolidated revenue grew 23% and EBITDA and PAT grew 25%; India volume grew 11% and India revenue grew 21%; international business grew 15% in constant currency. Management said it expects India high single-digit volume growth, international mid-teens constant currency growth, double-digit revenue growth to cross INR 15,000 crores, and high-teens EBITDA growth (aspiring to 20%) for the full year. Management said copra prices are expected to be range bound around 35% lower than last year's peak, while crude and vegetable oil input costs are expected to be relatively higher in Q2. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Aug 2026 | presentation Results | Please find enclosed the Information Update along with an earnings presentation on the un-audited consolidated financial results of the Company for the quarter ended June 30, 2026.AI summaryMarico filed an Information Update with an earnings presentation on its unaudited consolidated results (Marico Limited and subsidiaries) for the quarter ended June 30, 2026 (Q1 FY27). India Business revenues rose 21% YoY and International Business revenues rose 29% YoY (in INR terms); consolidated revenue growth was 23%. Domestic volume growth was 11% and international constant currency growth (CCG) was 15%. Consolidated EBITDA grew 25% and consolidated PAT grew 20.7%, with the presentation citing EBITDA margin and PAT growth at multi-quarter highs. Over the two years to Q1 FY27, the presentation shows volume, revenue and PAT CAGRs of 10%, 23% and 17% respectively. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Aug 2026 | board outcome Results | Please find enclosed outcome of the Board Meeting held on August 4, 2026.AI summaryMarico Limited filed the outcome of its Board meeting held on August 4, 2026, which began at 11:15 a.m. and was scheduled to run until 5:00 p.m. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the statutory auditor's limited review reports (B S R & Co. LLP, dated August 4, 2026). The auditor did not review 3 subsidiaries with total revenues of Rs. 918 crores and net profit after tax of Rs. 162 crores (before consolidation adjustments); its conclusion is not modified on this point. The auditor also noted that 16 subsidiaries with total revenues of Rs. 464 crores and net profit after tax of Rs. 30 crores (before consolidation adjustments) were not reviewed; management states these are not material to the group. The filing does not state the headline revenue or profit figures for the quarter, and it contains no dividend, guidance or other announcements. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jul 2026 | transcript | This is to inform you that the Company will hold an investor/analyst conference call on Tuesday, August 4, 2026 at 6:00 p.m. (IST). During the call, the Management will comment on the financial results and operations for the quarter ended JAI summaryMarico Limited filed an intimation of an investor/analyst conference call on Tuesday, August 4, 2026 at 6:00 p.m. IST. The call will follow the announcement of results for the quarter ended June 30, 2026 (Q1FY27), with the Board approving results on August 4, 2026. Management to speak on the call: Mr. Saugata Gupta (Managing Director & CEO) and Mr. Pawan Agrawal (Group CFO & CEO - International Business). Audio recording and transcript will be published on the company website after the call. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | presentation | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Management of the Company will be attending investor conferences as per the details atAI summaryMarico Limited filed a schedule of its management's attendance at analyst and investor conferences under Regulation 30 of the SEBI LODR Regulations. The conferences listed are 360 ONE Capital (B&K) 16th Annual Investor Conference - TRINITY INDIA 2026 (Mumbai, Friday, May 29, 2026), J.P. Morgan India Consumer CEO Fireside Chat Series (virtual, Friday, May 29, 2026), BofA Securities 2026 India Conference (Mumbai, Tuesday, June 2, 2026) and Citi India Conference 2026 (Mumbai, Friday, June 5, 2026). The presentation used for these meetings is available on the company's website, and the schedule is subject to change. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2026 | transcript Acquisition, Dividend / buy-back, Guidance, Results | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, copy of transcript of the earnings conference call held on Tuesday, May 5, 2026 on the audited financial results and operations of thAI summaryMarico filed the transcript of its Q4 FY26 earnings conference call held on May 5, 2026, covering audited results for the quarter and year ended March 31, 2026. Saugata Gupta (MD & CEO) said FY26 saw multi-year highs in India volume growth, International constant currency growth and consolidated revenue; Foods exited the year at INR 1,000+ crores revenue and Premium Personal Care at INR 1,100+ crores ARR. Management guided to high single-digit volume growth in India and mid-teens constant currency growth in International for FY27, with consolidated double-digit revenue growth to cross INR 15,000 crores and high-teens EBITDA growth, subject to stable macros. Management said copra prices have corrected about 35% from peak, but vegetable oils and crude-linked inputs face upward pressure from Middle East tensions; price hikes are expected to neutralise input cost increases. Pawan Agrawal (Group CFO) said the high-teens EBITDA growth target assumes situations normalise soon; Gupta said the guidance was revised from mid-teens to high-teens, reflecting firmer copra visibility and profitable acquisitions. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 May 2026 | presentation Results | Please find enclosed the Information Update along with an earnings presentation on the audited consolidated financial results of the Company for the quarter and financial year ended March 31, 2026.AI summaryMarico filed an Information Update and earnings presentation on audited consolidated results for the quarter and financial year ended March 31, 2026. FY26: consolidated revenue growth of 26% in international business (20% constant currency); India volume growth of 8%; India business revenues up 28% YoY; international business revenues up 20% YoY in INR terms. FY26: consolidated EBITDA margin of 17.1%; consolidated EBITDA growth of 9%; consolidated PAT growth of 11% excluding one-offs; consolidated A&P spends growth of 15%. Q4FY26: international revenue growth of 22% (19% constant currency); India volume growth of 9%; consolidated EBITDA margin of 15.6%; consolidated EBITDA growth of 14%; consolidated PAT growth of 14%. Q4FY26: India business revenues up 21% YoY; international business revenues up 25% YoY in INR terms; consolidated A&P spends growth of 5%. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 May 2026 | dividend Dividend / buy-back, Results | This is to inform you that the Board of Directors of the Company has at its meeting held today i.e. May 5, 2026 inter-alia recommended a final equity dividend of Rs. 4.00 per equity share of Re. 1 each for the financial year 2025-26 subjectAI summaryMarico Limited's board met on May 5, 2026 and approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with unmodified audit opinions from the statutory auditors. The board recommended a final equity dividend for FY 2025-26 of Rs. 4.00 per equity share of Re. 1 each, subject to shareholder approval at the 38th AGM. The record date for the final dividend is Thursday, July 30, 2026, and payment is to be made on or before Saturday, September 5, 2026. The board also approved convening the 38th AGM on Thursday, August 6, 2026, at 9:00 a.m. IST through video conferencing and other audio-visual means. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 May 2026 | board outcome Dividend / buy-back, Results | Please find enclosed outcome of the Board Meeting held on May 5, 2026.AI summaryMarico Limited's Board, at its meeting on May 5, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with unmodified audit opinions from the statutory auditors (BSR & Co. LLP). The Board recommended a final equity dividend of Rs. 4.00 per equity share of Re. 1 each for FY 2025-26, subject to shareholder approval at the 38th AGM. Record date for the final dividend is Thursday, July 30, 2026; payment is to be made on or before Saturday, September 5, 2026. The Board approved convening the 38th AGM on Thursday, August 6, 2026 at 9:00 a.m. IST via video conferencing and other audio-visual means. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Apr 2026 | transcript | This is to inform you that the Company will hold an investor/analyst conference call on Tuesday, May 5, 2026 at 5:30 p.m. (IST). During the call, the Management will comment on the financial results and operations for the quarter and financAI summaryMarico Limited filed an intimation of an investor/analyst conference call to be held on Tuesday, May 5, 2026 at 5:30 p.m. IST. The call will follow the announcement of financial results for the quarter and year ended March 31, 2026, to be approved by the Board on May 5, 2026. Management will comment on the financial results and operations for Q4 and FY26; Saugata Gupta (Managing Director & CEO) and Pawan Agrawal (Group CFO & CEO - International Business) will represent the company. Audio recording and transcript of the call will be published on the company's website after the call. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Apr 2026 | acquisition Acquisition | Please find attached intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.AI summaryMarico Limited filed an update under Regulation 30 on an acquisition by its wholly owned subsidiary Marico South East Asia Corporation (MSEA). MSEA completed the acquisition of 75% of the total share capital of Skinetiq Joint Stock Company, a Vietnam company that owns the digital-first skincare brand 'Candid' and holds exclusive distribution rights in Vietnam for the brand 'Murad', on April 2, 2026. Skinetiq has become a subsidiary of MSEA and, consequently, a subsidiary of Marico Limited. The original proposal was intimated in a letter dated February 9, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Mar 2026 | presentation | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Management of the Company will be holding one-on-one/group meetings with investors in AI summaryMarico Limited filed a schedule of analyst/investor meetings under Regulation 30 of the SEBI Listing Regulations, dated March 9, 2026. Management will hold one-on-one and group meetings with investors in Singapore as part of a Non-Deal Roadshow organised by J.P. Morgan India Private Limited, on March 24, 2026 and March 25, 2026. The company's presentation for such meetings is available on its website at marico.com/india/investors. The schedule is subject to change, and no unpublished price sensitive information will be shared at the meetings. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Feb 2026 | transcript Acquisition, Capex, Guidance | Further to our letter dated February 17, 2026, please find enclosed copy of transcript of the conference call held on Friday, February 13, 2026 on the announcement of recent strategic investments. The said transcript is also available on thAI summaryMarico filed the transcript of its conference call held on February 13, 2026, on recent strategic investments in India and Vietnam. Management said it targets 3x to 3.5x revenue growth in the digital acquisitions by FY30, and expects all digital brands globally to collectively reach at least around INR4,000 crores top line in FY30. Management said 4700BC is currently an EBITDA bleed, with a target to become EBITDA positive in the next 12 to 18 months and mid-to-high single-digit EBITDA in the next three years. Management said digital-first PPC brands are committed to about double-digit operating margin by FY27 and teens EBITDA margin over the next three to four years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Feb 2026 | transcript | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, copy of transcript of the conference call held on Friday, February 13, 2026 on the announcement of recent strategic investments, is eAI summaryMarico Limited filed the transcript of its conference call held on Friday, February 13, 2026, on the announcement of recent strategic investments. The filing is a cover letter under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, enclosing the transcript. The transcript is also available on the company's website. The pages provided do not include the call content, so management's remarks and tone cannot be summarised from this filing. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | presentation Acquisition, Capex, Guidance | Marico Limited has informed the Exchange about Investor PresentationAI summaryMarico Limited filed the presentation for its investor/analyst conference call held on February 13, 2026 at 3:30 p.m. (IST). The presentation is titled "Transforming into a digital-first powerhouse" (February 2026) and is also published on the company website. The pages shown cover the digital imperative: India active internet users of 96 Cr, D2C market growth of 3x by 2030, and e-commerce growth of ~19% (2025-30 CAGR). The pages also outline a strategic framework with five pillars: evidence-backed acquisitions, operational discipline, synergy acceleration, prudent capital allocation and a repeatable playbook. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Feb 2026 | presentation Acquisition | This is to inform you that the Company will hold an investor/analyst conference call on Friday, February 13, 2026 from 3:30 p.m. (IST) to 4:30 p.m. (IST). This conference call follows the announcement of recent strategic investments in Zea AI summaryMarico Limited has announced an investor/analyst conference call on Friday, February 13, 2026, from 3:30 p.m. to 4:30 p.m. IST. The call follows the announcement of recent strategic investments in Zea Maize Pvt. Ltd., Cosmix Wellness Pvt. Ltd. in India, and Skinetiq Joint Stock Company in Vietnam. Managing Director & CEO Saugata Gupta and Group CFO & CEO (International Business) Pawan Agrawal will represent the company and provide a perspective on the investments, followed by an interactive Q&A. The presentation will be filed with the stock exchanges and published on the company's website before the call; no unpublished price sensitive information will be shared. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Feb 2026 | acquisition Acquisition | Please find attached intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.AI summaryMarico Limited filed an intimation under Regulation 30 that its wholly owned subsidiary Marico South East Asia Corporation (MSEA) has entered into definitive agreements to acquire 75% of the shares of Skinetiq Joint Stock Company, a Vietnam-incorporated beauty company owning the "Candid" skincare brand and exclusive Vietnam distribution rights for "Murad". Aggregate consideration is up to VND 750 billion (INR 261.6 Cr), paid in cash in two tranches: VND 637.5 billion (INR 222.3 Cr) on receipt of 75% of shares, and VND 112.5 billion (INR 39.3 Cr) subject to certain conditions. Skinetiq's turnover was VND 443 billion (INR 152 Cr) in CY2025, against VND 181 billion (INR 61 Cr) in CY2024 and VND 131 billion (INR 45 Cr) in CY2023 (unaudited). Completion is expected within 90 days of signing, subject to Vietnam Department of Finance approval; the press release gives an equity valuation of c.INR 350 Cr. Saugata Gupta, MD and CEO, said the investment reflects commitment to building a strong premium beauty play in Vietnam and advancing the D2C strategy internationally. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2026 | acquisition Acquisition | Please find attached intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.AI summaryMarico Limited filed an update under Regulation 30 of the SEBI LODR Regulations, 2015, on its acquisition of 60% of the paid-up share capital of Cosmix Wellness Private Limited, the owner of the brand "Cosmix". The company had informed the exchanges on February 4, 2026 that it had entered into definitive agreements for this acquisition. The transaction was completed on February 5, 2026, and Cosmix Wellness Private Limited has become a subsidiary of Marico Limited. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Feb 2026 | acquisition Acquisition | Please find attached intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015AI summaryMarico Limited has entered into definitive agreements to acquire 60% of the paid-up share capital of Cosmix Wellness Private Limited, owner of the 'Cosmix' functional wellness brand, through a secondary buyout from its Founders. Aggregate consideration is Rs. 225.67 crores in cash; the press release cites an equity valuation of c.Rs. 375 crores, and the acquisition will make Cosmix Wellness a subsidiary of Marico. Completion is likely within 30 days, subject to customary closing conditions; no governmental or regulatory approvals are required per the filing. Cosmix Wellness turnover was Rs. 50.93 crores in FY 2024-25, Rs. 24.32 crores in FY 2023-24 and Rs. 5.39 crores in FY 2022-23; last 6 months ARR is about Rs. 100 crores. Marico has the right to acquire the remaining stake after FY29, at a consideration to be determined then, subject to milestones and approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Feb 2026 | presentation | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Management of the Company will be attending the following investor conference as per tAI summaryMarico Limited filed a schedule of an analyst/investor meeting under Regulation 30 of the SEBI LODR Regulations. The Management will attend a one-on-one meeting at the Nuvama India Conference - 2026 on Wednesday, February 11, 2026, in Mumbai. The schedule is subject to change, and no unpublished price sensitive information will be shared at the meetings. The presentation used for such meets is made available on the Company's website. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2026 | transcript Acquisition, Guidance, Results | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, copy of transcript of the earnings conference call held on Tuesday, January 27, 2026 on the un-audited financial results and operatioAI summaryMarico filed the transcript of its Q3FY26 earnings conference call, held January 27, 2026, on the unaudited results for the quarter and nine months ended December 31, 2025. Management (Saugata Gupta, MD & CEO) said demand remained stable, India volume growth improved sequentially, and more than 95% of franchises gained or sustained market share. Management said it strategically invested in premium gourmet snacking brand 4700BC, which is clocking about INR 140 crore ARR in the last three months, with a target to scale ARR to 3x in three years. Management expects Premium Personal Care ARR to exit the year at INR 350+ crore and the Digital-First portfolio to exit FY26 at INR 1,000+ crore ARR. Management expects progressive improvement in operating profit growth rates over coming quarters as input costs ease. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jan 2026 | acquisition Acquisition | Please find attached intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015AI summaryMarico Limited filed an update under Regulation 30 of the SEBI LODR Regulations on its acquisition of Zea Maize Private Limited. The acquisition of 93.27% of the paid-up share capital of Zea Maize, owner of the brand "4700BC", from PVR INOX Limited was completed on January 29, 2026. With completion, Zea Maize has become a subsidiary of Marico Limited. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jan 2026 | presentation Results | Please find enclosed the Information Update along with an earnings presentation on the un-audited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2025.AI summaryMarico filed an Information Update with earnings presentation on unaudited consolidated results (Marico Limited and subsidiaries) for the quarter and nine months ended December 31, 2025. India business revenues rose 28% YoY in Q3FY26, with 8% volume growth; international business revenues rose 24% YoY in INR terms and 21% in constant currency. Consolidated figures for Q3FY26 showed 27% revenue growth, 11% EBITDA growth, 12% PAT growth, 16.7% EBITDA margin and 15% growth in A&P spends. Management said consumption momentum is stable and demand trends are expected to gradually improve, and that 95%+ of the India business gained or sustained market share on a MAT basis. Parachute and Saffola continue to show pricing inelasticity; Value Added Hair Oils grew 50% in Q3 value terms, while Saffola Edible Oils grew 29% in Q3 value terms. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jan 2026 | board outcome Results | Please find enclosed outcome of the Board Meeting held on January 27, 2026AI summaryMarico Limited filed the outcome of its board meeting held on January 27, 2026, in which the board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Statutory Auditors' (B S R & Co. LLP) limited review report on the consolidated results is enclosed and states nothing has come to their attention that the statement has not disclosed required information or contains a material misstatement. The auditors did not review interim results of 4 subsidiaries (quarter revenue Rs. 915 crores; nine-month revenue Rs. 2,471 crores) and relied on other auditors' reports. The board meeting commenced at 11:00 a.m. and was scheduled to continue till 4:30 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Jan 2026 | acquisition Acquisition | Please find attached intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015AI summaryMarico Limited has entered into definitive agreements to acquire 93.27% of the paid-up share capital of Zea Maize Private Limited, owner of the premium gourmet snacking brand '4700BC', from PVR INOX Limited. Aggregate cash consideration is up to Rs. 226.83 crores; on completion Zea Maize becomes a subsidiary of Marico, with completion likely within 30 days subject to customary closing conditions. Zea Maize's turnover was Rs. 98.66 crores in FY 2024-25, Rs. 75.29 crores in FY 2023-24 and Rs. 48.47 crores in FY 2022-23; last 3 months ARR (Oct to Dec 2025) is about Rs. 140 crores. Marico has a right to acquire the remaining stake after 3 years from execution, at a consideration to be determined then, subject to milestones and approvals. Saugata Gupta, MD and CEO of Marico, said the investment aligns with the company's ambition to participate in fast-growing food categories through distinctive brands. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Jan 2026 | transcript | This is to inform you that the Company will hold an investor/analyst conference call on Tuesday, January 27, 2026 at 6:00 p.m. (IST). During the call, the Management will comment on the financial results and operations for the quarter endedAI summaryMarico Limited filed an intimation of an investor/analyst conference call on Tuesday, January 27, 2026 at 6:00 p.m. IST. The call will discuss financial results and operations for the quarter ended December 31, 2025 (Q3FY26), following the Board meeting on January 27, 2026. Managing Director & CEO Saugata Gupta and Group CFO & CEO - International Business Pawan Agrawal will represent the company on the call. An audio recording and transcript will be published later on the company's website. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Dec 2025 | acquisition Acquisition | Please find attached intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.AI summaryMarico Limited filed an update under Regulation 30 on its acquisition of Satiya Nutraceuticals Private Limited, owner of the brand "PLIX". Marico has already acquired an aggregate 60% stake on a fully diluted basis in Satiya Nutraceuticals, as previously disclosed on July 26, 2023, November 30, 2023 and May 31, 2025. The definitive agreement(s) were amended to extend by 12 months the period in which Marico can acquire the remaining 40% stake, in one or more tranches, subject to mutually agreed milestones and conditions. The remaining 40% stake acquisition right was originally exercisable at the expiry of 3 years from execution (during FY27); it is now extended accordingly. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Nov 2025 | transcript Guidance, Results | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, copy of transcript of the earnings conference call held on Friday, November 14, 2025 on the un-audited financial results and operatioAI summaryMarico Limited filed the transcript of its Q2 FY26 earnings conference call held on November 14, 2025, on results for the quarter and half year ended September 30, 2025. Management said India volume grew 7% in Q2 despite GST-related trade destocking in September, with the impact estimated at about 2% of volume in the quarter. Management said Parachute volume was flattish amid copra price hyperinflation, Saffola oils were flattish in volume, and Foods growth of 12% is expected to return to higher growth by Q4. Management said it continues to target around 25% consolidated revenue growth for the year, aims for double-digit EBITDA growth in the second half, and expects to reach Rs. 20,000 crores revenue by 2030. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.